Goldman Sachs has closed a $650 million fund focused on biotech investments, making it one of the largest first-time private life sciences growth funds. The West Street Life Sciences I fund will be managed by Goldman Sachs Asset Management’s Life Sciences Investing Group and will target early to mid-stage therapeutic companies, as well as life sciences tools and diagnostics companies. The fund has already allocated $90 million to five companies in its portfolio. Goldman Sachs highlighted several themes of fundamental innovation, including precision medicine, genetic medicine, cell therapy, immunotherapy, synthetic biology, and artificial intelligence, as drivers of future growth in the life sciences sector. Despite declining fundraises for biopharma, Goldman Sachs’ $650 million fund offers reassurance to the industry.
Goldman Sachs seals $650M biotech fund—unveiling an alluring investment prospect!
Latest from Blog
Arch Venture Partners secures over $3bn for Fund XIII
TLDR: Arch Venture Partners has raised over $3 billion for Fund XIII. Investors in the fund include Alaska Permanent Fund and Rockefeller Brothers Fund. In a recent development, Arch Venture Partners has
Raising Your First Venture Fund: Tips for Success
TLDR: Samir Kaji, a seasoned venture capital professional, shares a six-point plan for raising a venture fund as a first-time fund manager. Key steps include staying focused on a niche, not worrying
Exploring China’s Quantum Computing Breakthrough and VC Trends
TLDR: ONCO stock surged over 80% in pre-market after Altos Venture acquired a stake Chinese low float stocks like DUO rose over 40% in sympathy with large caps Summary: The article discusses
The Blindspot: Venture Capitalists’ Go-To Tool with Fatal Flaw
TLDR: Nader Al-Naji, founder of Bitclout, was arrested for an alleged crypto scam involving VC giant Andreessen Horowitz as a victim. VCs’ pattern matching led them to invest in Al-Naji despite red
Korean startups seek corporate investors in challenging ecosystem climate
TLDR: Korean startups are seeking corporate investors as funding becomes harder to secure. The government in South Korea has relaxed CVC rules to attract more foreign investment. Korean startups are facing a